Fatemeh Safari | Cancer Therapy | Women Researcher Award

Posted on by ScienceFather

Assist Prof Dr. Fatemeh Safari | Cancer Therapy | Women Researcher Award

Associate Professor at University of Guilan, Iran

Dr. Fatemeh Safari is an accomplished academic and researcher currently serving as an Associate Professor at the University of Guilan, Iran. She holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University, Japan, and has extensive postdoctoral experience at prestigious institutions, including the University of Tokyo and NAIST. Dr. Safari has made significant contributions to the field of microbiology and cancer research, with numerous publications in reputable journals and books. Her work explores the molecular mechanisms underlying cancer progression and treatment, focusing on the therapeutic potential of stem cell secretomes and natural compounds like green tea extracts. Awarded multiple fellowships, including the JSPS Fellowship and Monbukagakusho Scholarship, she has established herself as a leading researcher. Dr. Safari’s expertise is complemented by her commitment to mentoring students and her active involvement in academic collaborations. Her research continues to impact the scientific community, enhancing our understanding of cancer biology and potential therapies.

Profile

Education

Assistant Professor Dr. Fatemeh Safari holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University in Sapporo, Japan, where she completed her degree in 2011. Prior to her doctoral studies, she earned a Master’s degree in Microbiology from the University of Tehran in 2005, further solidifying her foundational knowledge in the biological sciences. Dr. Safari began her academic journey with a Bachelor’s degree in Biology, obtained from the University of Shahid Beheshti in Tehran, Iran, in 1999. Her diverse educational background encompasses a strong focus on molecular and cellular mechanisms, equipping her with the expertise necessary for her research in cancer biology and regenerative medicine. Dr. Safari’s academic achievements reflect her commitment to advancing scientific knowledge and contributing to the fields of microbiology and molecular biology.

Professional Experience

Prof. Dr. Fatemeh Safari has extensive experience in academia and research. Currently, she serves as an Associate Professor at the University of Guilan, Iran, since September 2022, where she has made significant contributions to the field of Molecular and Cellular Biology. Prior to this role, she was an Assistant Professor at the same institution from September 2016 to 2022. Dr. Safari gained valuable research experience as a Postdoctoral Fellow at prestigious institutions in Japan, including NAIST from 2014 to 2015 and The University of Tokyo from 2012 to 2014. Earlier in her career, she worked as a Research Assistant at the University of Tehran from 2005 to 2007. Throughout her career, Dr. Safari has focused on innovative research in microbiology and cancer biology, publishing extensively in reputable journals and contributing to various collaborative research projects. Her academic journey reflects her dedication to advancing scientific knowledge and mentoring future generations of researchers.

Research Interest

Professor Dr. Fatemeh Safari’s research interests lie at the intersection of molecular and cellular biology, with a particular focus on cancer biology, stem cell therapy, and drug development. Her work delves into understanding the molecular mechanisms underlying cancer progression and the potential therapeutic effects of mesenchymal stem cell (MSC) secretomes on various cancer types, including breast and colon cancers. Dr. Safari’s research also explores the modulation of cellular signaling pathways by natural and synthetic compounds, aiming to develop innovative anti-cancer agents. Her investigations into molecular docking, drug synthesis, and the bioactivity of green tea extracts highlight her commitment to finding novel therapeutic approaches. Additionally, she is involved in the development of advanced methodologies, such as spheroid formation and co-culture systems, to study tumor microenvironments. Dr. Safari’s research is highly interdisciplinary, contributing to the fields of oncology, pharmacology, and biotechnology.

Research Skills

Prof. Dr. Fatemeh Safari possesses a diverse array of research skills that significantly contribute to her expertise in molecular and cellular biology. Her extensive experience in microbiology and cancer research equips her with a robust foundation in experimental design and methodology. Proficient in advanced techniques such as molecular docking, cell culture, and the development of in vitro cancer models, she adeptly investigates cellular signaling pathways and the effects of various compounds on cancer cell behavior. Dr. Safari’s analytical skills are demonstrated through her numerous publications, showcasing her ability to synthesize complex data and draw meaningful conclusions. Additionally, her familiarity with both traditional and innovative approaches in microbiology allows her to explore interdisciplinary research opportunities. As a result, she is not only a proficient researcher but also a valuable mentor to emerging scientists, fostering a collaborative and innovative research environment in her laboratory.

Award and Recognition

Prof. Dr. Fatemeh Safari is a distinguished academic in the field of Molecular & Cellular Biology, recognized for her significant contributions to cancer research. She holds a Ph.D. from Hokkaido University and has garnered prestigious fellowships, including the Monbukagakusho Scholarship and the Japan Society for the Promotion of Science Fellowship. As an Associate Professor at the University of Guilan, she has published over 30 research articles in reputable journals and co-authored several book chapters, focusing on the molecular mechanisms of cancer and the therapeutic potential of stem cell secretomes. Her innovative research has earned her recognition within the academic community, and she actively participates in international conferences, sharing her findings and insights. Prof. Dr. Safari’s dedication to advancing scientific knowledge, coupled with her mentorship of emerging researchers, underscores her impactful role in the scientific community, making her a deserving candidate for the Best Researcher Award.

Conclusion

Professor Dr. Fatemeh Safari is a distinguished academic and researcher in the field of Molecular & Cellular Biology, with significant contributions to cancer research and regenerative medicine. Her extensive educational background, including a Ph.D. from Hokkaido University, complements her impressive publication record, featuring numerous articles in reputable journals. As an Associate Professor at the University of Guilan, she has demonstrated leadership in academia while mentoring students and collaborating on innovative research projects. Dr. Safari’s research focuses on the therapeutic potential of human adipose-derived mesenchymal stem cells (hAMSCs) in cancer treatment, highlighting her commitment to advancing scientific knowledge. Her recognition through prestigious fellowships, such as the JSPS Fellowship, underscores her international standing in the scientific community. With her blend of expertise, experience, and a dedication to research excellence, Professor Dr. Fatemeh Safari is a strong candidate for the Best Researcher Award, embodying the qualities of a leading scholar in her field.

Publication Top Notes
  1. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways
    • Authors: Rasouli, M., Alavi, M., D’Angelo, A., Roudi, R., Safari, F.
    • Year: 2024
    • Journal: International Immunopharmacology
    • Volume/Page: 143, 113265
    • Citations: 0
  2. Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents
    • Authors: Aghahosseini, F., Bayat, M., Sadeghian, Z., Gheidari, D., Safari, F.
    • Year: 2024
    • Journal: PLoS ONE
    • Volume/Issue/Page: 19(9), e0306973
    • Citations: 0
  3. TCAA-promoted novel approach synthesis and in vitro anti-cancer activity evaluation of spiro[indolo[2,1-b]quinazoline-6,4′-pyrano[2,3-c]pyrazole]-5′-carboxamides
    • Authors: Sadeghian, Z., Bayat, M., Eskandari, M., Safari, F.
    • Year: 2024
    • Journal: Results in Chemistry
    • Volume/Page: 9, 101636
    • Citations: 1
  4. The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
    • Authors: Safari, F., Bararpour, S., Omidi Chomachaei, F.
    • Year: 2024
    • Journal: Investigational New Drugs
    • Volume/Issue/Page: 42(3), pp. 272–280
    • Citations: 1
  5. Regulation of Cellular-Signaling Pathways by Mammalian Proteins Containing Bacterial EPIYA or EPIYA-Like Motifs Predicted to be Phosphorylated
    • Authors: Rasouli, M., Safari, F., Sobhani, N., Alavi, M., Roudi, R.
    • Year: 2024
    • Journal: DNA and Cell Biology
    • Volume/Issue/Page: 43(2), pp. 74–84
    • Citations: 1
  6. IRTKS Elevation in Patients with Colon Cancer and the Curative Influences of Hamsc Secretome on Polarity and Invasion of HT-29 Colon Cancer Cells
    • Authors: Khodabandeh, A., Safari, F., Ebadi Zavieh, S., Mirzanejad, L.
    • Year: 2024
    • Journal: Regenerative Engineering and Translational Medicine
    • Citations: 0
  7. Harnessing Nanotechnology for Idarubicin Delivery in Cancer Therapy: Current Approaches and Future Perspectives
    • Authors: Safari, F., Jalalian, Y., Abdouss, H., Fathi-Karkan, S., Pandey, S.
    • Year: 2024
    • Journal: BioNanoScience
    • Citations: 2
  8. Synthesis, Molecular Docking, and Biological Evaluation of Pyridin-3-yl-Pyrimidin-2-yl-Triazole Derivatives as Anti-cancer Agents
    • Authors: Firoozpour, L., Moghimi, S., Fallah Barzegar, M.H., Safari, F., Foroumadi, A.
    • Year: 2024
    • Journal: Polycyclic Aromatic Compounds
    • Volume/Issue/Page: 44(3), pp. 2062–2076
    • Citations: 1
  9. Synthesis and Biological Evaluation of 12-Aryl-11-hydroxy-5,6-dihydropyrrolo[2″,1″:3′,4′]pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-8(9H)-one Derivatives as Potential Cytotoxic Agents
    • Authors: Barghi Lish, A., Foroumadi, A., Kolvari, E., Safari, F.
    • Year: 2023
    • Journal: ACS Omega
    • Volume/Issue/Page: 8(45), pp. 42212–42224
    • Citations: 1
  10. Evaluation of SgK269 expression in colon cancer patients and the effects of hAMSCs secretome on tumor invasion through SgK269/c-Src/p-P130Cas/p-Paxillin/p-ERK1/2 signaling pathway in HT-29 colon cancer cells
    • Authors: Safari, F., Ansari Dogaheh, F., Dadashi, H.
    • Year: 2023
    • Journal: 3 Biotech
    • Volume/Issue/Page: 13(11), 346
    • Citations: 1

 

 

Mohammad Reza (Nima) Darbandi | Breast Cancer | Best Researcher Award

Posted on by ScienceFather

Mr. Mohammad Reza (Nima) Darbandi | Breast Cancer | Best Researcher Award

PhD candidate of University of Georgia, United States.

Nima Darbandi is a Ph.D. student in Computer Science at the University of Georgia, where he also serves as a research and teaching assistant. His research focuses on optimizing the llama.cpp framework and developing AI systems for domain detection using DNS logs. Nima has extensive experience in teaching subjects like Discrete Mathematics and Computer Networks. He has held various roles in the industry, including Linux Expert at Parspack Cloud Services, Consultant at Monenco Industry Group, and Chief Technical Officer at HamyarNet ISP. Nima’s research skills encompass AI, computer networks, and system administration, with a strong foundation in Network+, CCNA, and Linux Essentials. His contributions to artificial intelligence and disease treatment highlight his innovative approach and interdisciplinary expertise. He has been recognized with several awards, including the Outstanding Teaching Assistant Award from the University of Georgia.

Professional Profiles:

Education

Nima Darbandi is currently pursuing his Ph.D. in Computer Science at the University of Georgia, Athens, GA, USA, starting in the fall of 2022. He earned his M.S. in Information Technology from the Iran University of Science and Technology, Tehran, IRAN, where he conducted a dissertation titled “A New Method to Estimate QoE for Internet Users” from 2011 to 2015. Before that, he completed his B.S. in Information Technology at Shiraz University of Technology, Shiraz, IRAN, between 2006 and 2010.

Professional Experience

Nima Darbandi has a diverse professional background in both academia and industry. As a Research/Teaching Assistant at the University of Georgia, he worked on llama.cpp framework optimization and AI systems for DNS logs under Dr. Agrawal, Dr. Niu, and Dr. Perdisci from 2022 to 2024, while also teaching Discrete Mathematics and Computer Networks. In the industry, he served as a Linux Expert at Parspack Cloud Services in Tehran from 2021 to 2022, and as a Consultant for Monenco Industry Group from 2020 to 2022, where he developed a Dispatching System on CISCO telephony. Nima held the position of Chief Technical Officer at HamyarNet ISP from 2017 to 2020, overseeing ADSL and P2P wireless Internet services. He founded Puzzle Network Solutions, focusing on network services and devices, from 2014 to 2017, and was a Senior Manager at SabaNet ISP from 2009 to 2014. He also has extensive teaching experience, providing Network+, CCNA, Linux Essentials, and Computer Networking courses across several institutions in Shiraz from 2007 to 2018.

Research Interest

Nima Darbandi’s research interests lie primarily in the fields of computer science, information technology, and artificial intelligence. He is particularly focused on optimizing AI frameworks, such as llama.cpp, and utilizing AI for domain-specific applications like DNS log analysis. His work includes enhancing the quality of experience (QoE) for internet users, which was the subject of his M.S. dissertation. Nima is also interested in developing AI-driven solutions for early diagnosis and precision treatment in healthcare, as evidenced by his publication on AI breakthroughs in breast cancer treatment. Additionally, his research spans into network management, cloud hosting services, and cybersecurity, showcasing a broad interest in both theoretical and applied aspects of computing and technology.

Award and Honors

Nima Darbandi has received several awards and honors throughout his academic and professional career. In 2023, he was honored with the Outstanding Teaching Assistant Award from the University of Georgia, recognizing his excellence in teaching and support for students. In 2016, he received the Best Supporter and Advisor Token of Appreciation from Kavosh, highlighting his contributions and advisory role. Earlier, in 2013, he was awarded the Outstanding Network Expert Token of Appreciation from SabaNet ISP for his expertise and dedication in the field of network services. Additionally, in 2007, he secured the Third Rank Token of Appreciation from Shiraz University of Technology, acknowledging his academic achievements during his undergraduate studies. These accolades reflect his commitment to both teaching and technical proficiency.

 Research Skills

Nima Darbandi possesses a diverse set of research skills, honed through extensive academic and professional experiences. His expertise includes optimizing the llama.cpp framework and developing AI systems for domain detection using DNS logs. He is proficient in various aspects of computer networks, evidenced by his teaching roles in Discrete Mathematics and Computer Networks. His background in Linux, cloud hosting, and virtualization (VMware VCenter) further strengthens his technical prowess. Additionally, Nima has practical experience with Network+, CCNA, and Linux Essentials, reflecting his broad knowledge in networking and system administration. His research contributions in artificial intelligence, particularly in early diagnosis and precision treatment of diseases, underscore his interdisciplinary approach and innovation in the field.

 

 

Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Dr. Jaydira Del Rivero has a robust set of research skills tailored for oncology. Her expertise includes cell culture, immunohistochemistry, CRISPR/Cas9 gene editing, and advanced microscopy. Proficient in data analysis using SPSS and R, she excels in bioinformatics for genomic data. Dr. Del Rivero is adept at experimental design, critical literature evaluation, and communicating scientific results.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

 Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications
  1. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (4), 351-355
    Citations: 238
  2. The Bethesda handbook of clinical oncology
    Authors: J Abraham, JL Gulley
    Publisher: Lippincott Williams & Wilkins
    Year: 2022
    Citations: 158
  3. Anti–PD-L1 treatment induced central diabetes insipidus
    Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
    Journal: The Journal of Clinical Endocrinology & Metabolism
    Year: 2018
    Volume/Issue: 103 (2), 365-369
    Citations: 104
  4. Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
    Authors: N Makita, T Iiri
    Journal: Thyroid
    Year: 2013
    Volume/Issue: 23 (2), 151-159
    Citations: 99
  5. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
    Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
    Journal: Surgery
    Year: 2016
    Volume/Issue: 159 (1), 302-310
    Citations: 93
  6. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
    Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
    Journal: Journal of Bone and Mineral Research
    Year: 2016
    Volume/Issue: 31 (10), 1845-1854
    Citations: 87
  7. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
    Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
    Journal: Pancreas
    Year: 2021
    Volume/Issue: 50 (4), 469-493
    Citations: 77
  8. Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
    Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
    Journal: Endocrine-Related Cancer
    Year: 2016
    Volume/Issue: 23 (12), 899-908
    Citations: 76
  9. Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
    Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
    Journal: The Oncologist
    Year: 2020
    Volume/Issue: 25 (4), 290-300
    Citations: 72
  10. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
    Authors: JE Faris, AF Moore, GH Daniels
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (11), 1147-1149
    Citations: 72

 

 

Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Medical Director, Oncology Service Line, Sutter Health at California Pacific Medical Center Research Institute, United States.

Dr. Mohammed Kashani-Sabet is a distinguished medical professional with extensive expertise in dermatology and oncology. Holding multiple leadership positions, including Medical Director of the Oncology Service Line at Sutter Health and the Cancer Center at California Pacific Medical Center, he has made significant contributions to cancer research and treatment. Dr. Kashani-Sabet received his medical education from renowned institutions such as Harvard University and the State University of New York at Stony Brook. Throughout his career, he has been involved in groundbreaking research focused on melanoma, cutaneous T-cell lymphoma, targeted therapy, and tumor biomarkers. He has received numerous honors and awards for his contributions to the field, including the Clinical Career Development Award from the Dermatology Foundation and the Patients’ Choice Award by Sutter Medical Network. Dr. Kashani-Sabet’s dedication to improving patient care and advancing cancer treatment has earned him widespread recognition and respect in the medical community.

Professional Profiles:

Education:

Dr. Mohammed Kashani-Sabet embarked on his academic journey with a Bachelor’s degree in Biochemical Sciences from Harvard University, followed by a Doctorate in Medicine from the State University of New York at Stony Brook. After completing his medical education, he undertook an internship in Internal Medicine and residency in Dermatology at the State University of New York at Stony Brook and the University of California, San Francisco (UCSF) respectively. Dr. Kashani-Sabet further honed his expertise through a post-doctoral fellowship in Cutaneous Oncology at UCSF’s Department of Dermatology and Division of Hematology/Oncology. This comprehensive educational background laid a robust foundation for his subsequent career as a renowned physician and researcher in the field of dermatology and oncology.

Professional Experience:

Dr. Mohammed Kashani-Sabet has held several prestigious positions throughout his career, demonstrating his leadership and expertise in the field of dermatology and oncology. Currently, he serves as the Medical Director of the Oncology Service Line at Sutter Health and as the Medical Director of the Cancer Center at California Pacific Medical Center. Additionally, he holds the position of Medical Director of the Center for Melanoma Research and Treatment at Sutter West Bay Medical Group, Sutter Pacific Medical Foundation, and California Pacific Medical Center. Dr. Kashani-Sabet also contributes significantly to research as a Senior Scientist at the California Pacific Medical Center Research Institute. His extensive professional experience spans over two decades and encompasses various roles in academia, clinical practice, and administrative leadership within prestigious institutions such as the University of California, San Francisco (UCSF) and the California Pacific Medical Center.

Research Focus:

Dr. Mohammed Kashani-Sabet’s research focus encompasses a broad spectrum of topics within dermatology and oncology, with a particular emphasis on melanoma and cutaneous T-cell lymphoma. His work includes investigating novel targeted therapies, such as ribozymes and siRNAs, for these malignancies. Additionally, he explores tumor metastasis, prognostic modeling, and tumor biomarkers to advance our understanding of these diseases and improve patient outcomes. Dr. Kashani-Sabet’s research efforts aim to translate scientific discoveries into clinical applications, with the ultimate goal of developing more effective treatments and interventions for patients with melanoma and cutaneous T-cell lymphoma.

Research Interest:

Dr. Mohammed Kashani-Sabet possesses a diverse set of research skills honed over years of experience in dermatology and oncology. His expertise includes clinical research, where he designs and conducts studies to evaluate novel therapies for melanoma and cutaneous T-cell lymphoma. In the laboratory, he is skilled in various techniques such as PCR, DNA sequencing, and gene expression analysis, essential for basic and translational research. Dr. Kashani-Sabet also excels in data analysis, utilizing statistical methods and software to interpret clinical and experimental data effectively. With a track record of publishing research findings in peer-reviewed journals, he demonstrates proficiency in scientific writing and manuscript preparation. Additionally, his ability to write grant proposals and collaborate with interdisciplinary teams underscores his commitment to advancing dermatologic oncology research and improving patient care.

Award and Honors:

Dr. Mohammed Kashani-Sabet has been recognized with numerous awards and honors throughout his career, reflecting his exceptional contributions to dermatologic oncology research and patient care. Among these accolades are the Clinical Career Development Award from the Dermatology Foundation in 1997 and the Herschel and Diana Zackheim Endowed Chair in Cutaneous Oncology in the same year. His dedication to teaching and mentorship was acknowledged with the Teacher of the Year Award in 2004, bestowed upon him by the Dermatology Residents at UCSF. Notably, Dr. Kashani-Sabet received the Patients’ Choice Award in 2013 from the Sutter Medical Network for achieving high patient satisfaction scores. His humanitarian efforts were recognized with the Humanitarian Award by the Melanoma Research Foundation in 2014. Moreover, he holds the Chair in Melanoma Research and Treatment at California Pacific Medical Center since 2015, a testament to his leadership and contributions to the field.

Publications:

  1. Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
    • Authors: Chang, S.H., Ice, R.J., Chen, M., … Soroceanu, L., McAllister, S.D.
    • Citations: 0
    • Year: 2023
  2. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
    • Authors: Kashani-Sabet, M., Leachman, S.A., Stein, J.A., … Venna, S., Kirkwood, J.M.
    • Citations: 6
    • Year: 2023
  3. Improving Selection for Sentinel Lymph Node Biopsy among Patients with Melanoma
    • Authors: Miller, J.R., Lo, S.N., Nosrati, M., … Scolyer, R.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2023
  4. Erratum: Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  5. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
    • Authors: Sidorov, M., Dighe, P., Woo, R.W.L., … McAllister, S.D., Soroceanu, L.
    • Citations: 7
    • Year: 2023
  6. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
    • Authors: Minor, D.R., Kim, K.B., Karuturi, R.K.M., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  7. Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients
    • Authors: Balkin, D.M., Tranah, G.J., Wang, F., … Zager, J.S., Leong, S.P.
    • Citations: 0
    • Year: 2023
  8. BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
    • Authors: Bezrookove, V., Khan, I.A., Nosrati, M., … Dar, A.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022
  9. Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
    • Authors: Chen, M., Jian, D., Sidorov, M., … McAllister, S.D., Desprez, P.-Y.
    • Citations: 2
    • Year: 2022
  10. Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022